Multinational clinical trials involving 30 institutions including Korea and the US… Evaluating safety and efficacy
Daewoong Pharmaceutical has started phase 2 international clinical trials for its new drug candidate for idiopathic pulmonary fibrosis, ‘versiporosin (DWN12088)’.
Daewoong Pharmaceutical announced on February 6 that it had completed the administration of the first patient for a phase 2 clinical trial of versiphorosin on January 31.
The phase 2 multinational clinical trial of versiporosin will be conducted at approximately 30 institutions in Korea and the United States, including Asan Medical Center in Seoul. In 102 patients, the safety of versiphorosin and the change in vital capacity improvement (FVC) after 24 weeks of administration of the test drug or placebo are evaluated.
With the aim of completing the administration of the test subjects and confirming the results by 2024, Daewoong Pharmaceutical proves the excellent anti-fibrotic effect and lung function improvement results of versiphorosin confirmed in the last non-clinical efficacy test through the scheme clinical trial this.
Professor Song Jin-woo (Department of Pulmonary Medicine, Seoul Asan Medical Center), who is overseeing the phase 2 clinical trial of versiporosin in Korea, said, “We expect this clinical trial to be of great help in developing a new treatment that complements the shortcomings of current treatments.” he said.
Daewoong Pharmaceutical CEO Lee Chang-jae said, “We have taken an important first step by completing the first dose of the phase 2 clinical trial. We plan to focus on strengthening our new drug development capabilities to ensure successful clinical outcomes.”
Copyright © Uihyup Newspaper Unauthorized reproduction and redistribution prohibited
<!– 추천반대
추천반대 –>
